Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Bioverativ Japan Now Up and Running, Set to Keep Double-Digit Growth: President
March 3, 2017
- NCC, Daiichi Sankyo Begin PI on Mutant IDH1 Inhibitor for Glioma
March 2, 2017
- Fujifilm Creates Bio CDMO Division, Aims for 100 Billion Yen Sales in FY2023
March 2, 2017
- GSK Remains Strong Player in Respiratory, Japan Sales Slip 1.7%: Fauchet
March 1, 2017
- Nobelpharma Forms Preparatory Office for Overseas Biz
March 1, 2017
- ASKA Gets Asian Rights to Pieris’ Anemia Med
March 1, 2017
- Astellas, Affinivax Ink Global Partnership on Pneumococcal Vaccine
March 1, 2017
- Novo Files Once-Weekly GLP-1 in Japan
March 1, 2017
- Tolero Aims to File for AML Treatment Alvocidib in FY2018 in US: Sumitomo Dainippon
March 1, 2017
- Takeda to Transfer Part of CMC Functions to Bushu
March 1, 2017
- Kyowa Earns Rights for Astellas’ Extended-Release Quetiapine
February 28, 2017
- Shionogi to Comarket Methapain with Terumo
February 28, 2017
- Alecensa Gets Approval in Taiwan: Chugai
February 28, 2017
- Sanofi Files Atopic Dermatitis Treatment Dupilumab in Japan
February 28, 2017
- LEO Pharma Applies for Gel Formulation for Dovobet
February 28, 2017
- Daiichi Sankyo to Set Up Brand Strategy Unit to Spur Cancer Biz
February 27, 2017
- Eisai’s Yuji Matsue to Spearhead EA Pharma
February 27, 2017
- Daiichi Sankyo Takes Aim at Top Spot in Japan Ethical Drug Market: Next President
February 27, 2017
- Koichi Shimada to Lead Alfresa Pharma
February 24, 2017
- Takeda, Astellas to Build Joint Storage and Distribution System in Hokkaido
February 24, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…